"The Pink Sheet" 
"The Gray Sheet" 
"The Tan Sheet" 
   
HomeSubscribeAdvertisingPast IssuesStaff My AccountHelpContact
Order Reprint
search within:
 


 August 7, 2008 Volume 20, Number 153 

Daily Content from Elsevier Global Medical News
Alefacept Ineffective in Chronic Alopecia Areata
Chicago — Alefacept fared no better than placebo in treating chronic, severe alopecia areata in a 12-week double-blind, randomized study of 45 adults.   READ MORE>>



Daily News from "The Gray Sheet"
FDA Continues Nanotech Policy Development With September Meeting
FDA will hold a meeting next month to hear views on what it should include in a set of guidelines in development on nanotechnology-based products, the agency announced this morning in the Federal Register.   READ MORE>>


News from "The Pink Sheet" DAILY
Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
After two “not approvable” letters, Pfizer’s Fablyn (lasofoxifene) at last is set for consideration Sept. 8 by FDA’s Advisory Committee for Reproductive Health Drugs.   READ MORE>>



Daily news from "The Tan Sheet"
“Disturbing” DHEA Ads, Hill Interest Prompt CRN’s Marketing Guidelines
The Council for Responsible Nutrition has adopted voluntary guidelines for marketing DHEA supplements in response to inaccurate advertising and to lawmakers’ interest in limiting access to the products.    READ MORE>>


HomeSubscribeAdvertisingPast IssuesStaff My AccountHelpContact

  FDC Reports is the publisher of "The Pink Sheet"; "The Pink Sheet" DAILY; "The Gray Sheet"; FDAAdvisoryCommittee.com; "The Tan Sheet"; "The Rose Sheet"; Pharmaceutical Approvals Monthly; "The Gold Sheet"; "The Silver Sheet"; Health News Daily; PharmAsia News, an Elsevier company.